vVARDIS and OrbiMed have announced the closing of a $35m financing. The capital will support the former’s growth initiatives and global commercial expansion. vVARDIS is a developer and manufacturer of dental products under the Curodont brand, including their drill-free treatment for early tooth decay. With tooth decay remaining the number one disease worldwide, according to the World Health Organisation, vVARDIS’ rapid sales expansion, with an initial focus on the US, has seen dental clinics using the product with over 300,000 teeth treated in 2024. vVARDIS’ technology has also been incorporated in lectures of universities in the US and Europe as a new standard of care for the treatment of early tooth decay.
The partnership between OrbiMed and vVARDIS is based on the shared goal to build a US and global leader in innovative dental products. With the market shifting from invasive to non-invasive care combined with the accelerated adoption of AI-detection of early tooth decay, vVARDIS products are well-timed to market trends. These products allow dental practices to treat early tooth decay in five to 10 minutes, saving dental professionals and patients hours of chair time.
“We are confident that vVARDIS has the scientific knowledge and capabilities to become a global powerhouse in the dental market. With its proprietary formulas and its Curodont products, the company is positioned to grow fast in this market and to provide a drill-free option for early tooth decay. The growth ambition of the company and its focus on providing innovative solutions in a global dental market are at the core of our investment strategy,” said Matthew Rizzo, general partner or OrbiMed.
“We are thrilled about the partnership with OrbiMed. The funding and the expertise they bring will enhance our abilities to better serve dental professionals and patients and to fulfill our vision to create a world where treatment of early decay is pain-free, regenerative and accessible to everyone. As dentists, we are excited to finally offer a solution for the treatment of early decay. Dental professionals have been waiting for decades for a drill-free treatment of early decay. Curodont has the potential to broaden the scope of options offered by dental practices and empowering them to enhance patient care,” commented Drs Haley and Goly Abivardi, founders and co-CEOs of vVARDIS
